CSIMarket
 
Achieve Life Sciences Inc   (ACHV)
Other Ticker:  
 
 
Price: $4.3200 $-0.11 -2.483%
Day's High: $4.62 Week Perf: -7.49 %
Day's Low: $ 4.30 30 Day Perf: 0.47 %
Volume (M): 63 52 Wk High: $ 10.30
Volume (M$): $ 271 52 Wk Avg: $5.28
Open: $4.45 52 Wk Low: $3.03



 Market Capitalization (Millions $) 91
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 0

Achieve Life Sciences Inc
Achieve Life Sciences Inc is a pharmaceutical company focused on developing and commercializing treatments for nicotine addiction. The company's lead product candidate is cytisine, a plant-based alkaloid that has been used for smoking cessation in Eastern Europe for several decades. Achieve Life Sciences aims to leverage the established efficacy and safety profile of cytisine to provide an effective and affordable treatment option for smokers looking to quit. The company is actively conducting clinical trials to evaluate the potential of cytisine as a smoking cessation therapy.


   Company Address: 1040 West Georgia Street Vancouver 0 BC
   Company Phone Number: 210-2217   Stock Exchange / Ticker: NASDAQ ACHV
   ACHV is expected to report next financial results on March 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Achieve Life Sciences Inc

Achieve Life Sciences Inc. exhibits remarkable progress during Q3 2023 earnings season with operating deficit improving to $-12.639 million

Achieve Life Sciences Inc, a company operating in the In Vitro & In Vivo Diagnostic Substances sector, has recently reported its financial results for the third quarter of 2023. The results indicate that the company has made significant progress in reducing its operating deficit compared to the same quarter last year.
During the past 5 trading days, Achieve Life Sciences Inc shares have experienced a slight decline of -1.67%. However, it is important to note that the year-to-date performance of the company stands at an impressive 62.45%. This suggests that Achieve Life Sciences Inc has performed well over the course of this year, despite the recent decline.

Achieve Life Sciences Inc

ACHV Corporation Earns Praise for $2.234 Million Reduction in Operating Shortfall, Outshines Competitors in Second Quarter 2023 Performance

The In Vitro & In Vivo Diagnostic Substances industry is attracting significant attention and analysis, with industry advisors closely scrutinizing the second quarter results of 2023. In particular, today these advisors have observed an operating shortfall of $-7.714 million from a company that has yet to specify any top-line figures for the April to June 30 reporting season. This is an intriguing situation as it suggests that the emerging growth corporation is conducting its business more cost-effectively than in the previous year's comparable period when it reported an operating shortfall of $-10.073 million.
One of the most promising revelations is that the deficit has receded to $-8.239 million from $-10.468 million in the second quarter of 2022. This positive trend is a significant development that will undoubtedly support the organization on its journey to emerge as a leader in the industry. It showcases the corporation's ability to effectively manage its financials and potentially points towards a brighter future.

Achieve Life Sciences Inc

ACHV Reports Surprising First Quarter Earnings in the Biotech & Pharma Industry

Achieve Life Sciences Inc has recorded a net loss of $-44 million for the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -322.41%. These are certainly not the results investors were hoping for. The Healthcare sector alone has 407 other companies that have performed better than Achieve Life Sciences Inc in terms of ROI.
However, it's worth noting that the company is moving in the right direction. The overall ROI ranking has progressed from 4971 in the fourth quarter of 2022 to 2366 in the first quarter of 2023. In the Biotechnology & Pharmaceuticals industry, Achieve Life Sciences Inc is trailing behind leaders and some lesser-known businesses are reporting better results.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com